Atlas Arteria urges shareholders to reject IFM’s $5.10 takeover bid

The Atlas Arteria Group (ASX: ALX) share price remains in focus after the company’s Independent Directors reaffirmed their unanimous recommendation for shareholders to reject the unsolicited takeover offer from IFM, citing the offer as materially undervaluing Atlas Arteria and confirming the company’s 40.0 cents per security 2026 distribution guidance.

What did Atlas Arteria report?

• The off-market cash takeover offer from IFM is $5.10 per Atlas Arteria security.
• The offer is 12% below the $5.79 midpoint of the Independent Expert’s valuation range of $5.39 to $6.20 per security.
• Atlas Arteria reconfirmed its 2026 ordinary distribution guidance of 40.0 cents per security.
• Any net proceeds from asset sales would be returned to securityholders in addition to the ordinary distribution.

What else do investors need to know?

Atlas Arteria’s Independent Directors have strongly advised securityholders to reject IFM’s current offer, arguing it does not reflect a full and fair value for the business, especially in light of the company’s global toll road portfolio and ongoing asset-sale process.

The company is progressing the planned sale of part or all of its 66.67% stake in the Chicago Skyway, with agreements expected to be signed in the fourth quarter of 2026. Proceeds from this and any other divestments are intended to be distributed to shareholders, representing additional value on top of existing distribution targets.

Management also noted confidence that taxes arising from the Chicago Skyway transaction are expected to be immaterial, with efficient return-of-capital arrangements under consideration.

What’s next for Atlas Arteria?

Atlas Arteria is targeting continued disciplined management, with a focus on long-term value creation and sustainable returns for its investors. The company reaffirmed its planned distribution of at least 40.0 cents per security in 2026, subject to ongoing business performance and market conditions.

Beyond the current offer period, Atlas Arteria will continue strategic asset reviews and may pursue further capital returns, while upholding its governance commitments and ensuring independent majority representation on its boards.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 5%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.

View Original Announcement

The post Atlas Arteria urges shareholders to reject IFM’s $5.10 takeover bid appeared first on The Motley Fool Australia.

More reading

• Qube shareholders vote on $5.20 takeover offer
• HomeCo Daily Needs REIT posts $92m valuation gain, reaffirms guidance
• Centuria Industrial REIT unveils data centre strategy
• Centuria Capital Group unveils AI-powered growth at Investor Day
• Contact Energy’s May 2026 report shows higher sales and lower costs

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.